Publications
Explore our latest scientific posters, presentations, and peer-reviewed publications that highlight the potential of our therapies to advance treatment for immune-mediated diseases.
Budoprutug
Preliminary Data from PrisMN, a Phase 2 Study Evaluating the Safety and Efficacy of Budoprutug, an Investigational Low-Fucosylated Anti-CD19 Monoclonal Antibody (mAb), in Patients with Primary Membranous Nephropathy (PMN)
Presented at ASN Kidney Week 2026
Poster: Budoprutug for Minimal Change Disease (MCD): A Case Study of Durable Response and Potential Disease Modification via CD19+ B-Cell Depletion
Presented at ASN Kidney Week 2026
Poster: Budoprutug, A Low-Fucosylated Anti-CD19 Monoclonal Antibody, In Adults With Primary Immune Thrombocytopenia: Initial Phase 1B Study Results
Presented at the EHA Congress June 11, 2026
Poster: PrisMN: Phase 2 Study to Evaluate the Safety and Efficacy of Budoprutug, a Low-Fucosylated Anti-CD19 mAb, in Primary Membranous Nephropathy »
Presented at the 63rd ERA Congress Glasgow & Virtual, June 3-6, 2026
Published Abstract: Long-Term Remission of Proteinuria in Primary Membranous Nephropathy After Four Doses of Budoprutug, a Novel Anti-CD19 Monoclonal Antibody »
Published as part of the American Society of Nephrology (ASN) Kidney Week, November 5-9, 2025
Poster: A Tunable Scalable Platform for Precise Fucosylation Control to Enhance Efficacy of Therapeutic Antibodies: Application to Clinical Manufacturing of Budoprutug »
Presented at PEGS Boston – The Essential Protein Engineering & Cell Therapy Summit, May 12-16, 2025
Poster: A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy (pMN) »
Presented at the American Society of Nephrology (ASN) Kidney Week, October 23-24, 2024
CLYM116
CLYM116, A Novel ‘Sweeper’ Anti-APRIL mAb in Development For IgAN: Phase 1 Safety, Tolerability, PK, and PD Results in Healthy Volunteers
Presented at ASN Kidney Week 2026
Poster: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MIL116, a Novel 'Sweeper' Anti-APRIL Monoclonal Antibody in Healthy Volunteers: Preliminary Phase 1 Results
Presented at ASN Kidney Week 2026
A Phase 2 Randomized, Parallel-Group, Open-Label Trialof MIL116,a Novel ‘Sweeper’ Anti-APRIL Monoclonal Antibody, in Participants with Immunoglobulin A Nephropathy
Presented at the ISN Frontiers Meeting September 5-7, 2026
Focused Oral: CLYM116, a Novel ‘Sweeper’ Anti-APRIL mAb: Extrapolation of PK and Ig Suppression from NHPs to Healthy Volunteers and Initial Phase 1 Data
Presented at the 63rd ERA Congress Glasgow & Virtual, June 3-6, 2026
Poster: Development and Characterization of CLYM116, A Novel FC-Engineered anti-APRIL mAb with pH-Dependent Binding for IgA Nephropathy
Presented at the American Society of Nephrology (ASN) Kidney Week, November 5-9, 2025